Michael Barnett
Michael Barnett
The University of Sydney / Brain and Mind Centre
Verified email at
Cited by
Cited by
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis
R Gold, L Kappos, DL Arnold, A Bar-Or, G Giovannoni, K Selmaj, ...
New England Journal of Medicine 367 (12), 1098-1107, 2012
Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion
MH Barnett, JW Prineas
Annals of Neurology 55 (4), 458-468, 2004
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ...
The Lancet 391 (10127), 1263-1273, 2018
Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis
CG Bien, A Vincent, MH Barnett, AJ Becker, M Blümcke, F Graus
Brain, 2012
Multiple sclerosis: distribution of inflammatory cells in newly forming lesions
APD Henderson, MH Barnett, JDE Parratt, JW Prineas
Annals of neurology 66 (6), 739-753, 2009
Immunopathology of secondary‐progressive multiple sclerosis
JW Prineas, EE Kwon, ES Cho, LR Sharer, MH Barnett, EL Oleszak, ...
Annals of neurology 50 (5), 646-657, 2001
The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis
V Devonshire, Y Lapierre, R Macdonell, C Ramo‐Tello, F Patti, ...
European journal of neurology 18 (1), 69-77, 2010
Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype
EK Mathey, SB Park, RAC Hughes, JD Pollard, PJ Armati, MH Barnett, ...
Journal of Neurology, Neurosurgery & Psychiatry 86 (9), 973-985, 2015
Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination
S Ramanathan, S Mohammad, E Tantsis, TK Nguyen, V Merheb, ...
Journal of Neurology, Neurosurgery & Psychiatry 89 (2), 127-137, 2018
The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects
A Minagar, MH Barnett, RHB Benedict, D Pelletier, I Pirko, MA Sahraian, ...
Neurology 80 (2), 210-219, 2013
The evidence for a role of B cells in multiple sclerosis
G Disanto, JM Morahan, MH Barnett, G Giovannoni, SV Ramagopalan
Neurology 78 (11), 823-832, 2012
Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis
S Ramanathan, K Prelog, EH Barnes, EM Tantsis, SW Reddel, ...
Multiple Sclerosis Journal 22 (4), 470-482, 2016
Defining secondary progressive multiple sclerosis
J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ...
Brain 139 (9), 2395-2405, 2016
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis
S Ramanathan, SW Reddel, A Henderson, JDE Parratt, M Barnett, ...
Neurology-Neuroimmunology Neuroinflammation 1 (4), 2014
The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion
MH Barnett, APD Henderson, JW Prineas
Multiple sclerosis 12 (2), 121-132, 2006
Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis
T Kalincik, D Horakova, T Spelman, V Jokubaitis, M Trojano, A Lugaresi, ...
Annals of Neurology 77 (3), 425-435, 2015
Immunoglobulins and complement in postmortem multiple sclerosis tissue
MH Barnett, JDE Parratt, ES Cho, JW Prineas
Annals of neurology 65 (1), 32-46, 2009
Exosomal microRNA signatures in multiple sclerosis reflect disease status
S Ebrahimkhani, F Vafaee, PE Young, SSJ Hur, S Hawke, E Devenney, ...
Scientific reports 7 (1), 1-10, 2017
CNS demyelination and quadrivalent HPV vaccination
I Sutton, R Lahoria, IL Tan, P Clouston, MH Barnett
Multiple Sclerosis Journal 15 (1), 116-119, 2009
A follow up study of patients with paraneoplastic neurological disease in the United Kingdom
PM Candler, PE Hart, M Barnett, R Weil, JH Rees
Journal of Neurology, Neurosurgery & Psychiatry 75 (10), 1411-1415, 2004
The system can't perform the operation now. Try again later.
Articles 1–20